vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2018-15-1-68-75vestim-415Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEПРОТИВОСУДОРОЖНОЕ ДЕЙСТВИЕ СТЕАРОИЛЭТАНОЛАМИНА В МОДЕЛИ ЭПИЛЕПТИЧЕСКОГО ПРИПАДКАANTICONVULSANT EFFECT OF STEAROYLETHANOLAMINE IN THE MODEL OF EPILETIC SEIZUREМелик-КасумовТ. Б.Melik-KasumovT. B.

канд. биол. наук, вед. науч. сотрудник

ул. Академическая, 28, 220072, г. Минск

Ph. D. (Biol.), Leading researcher

28, Akademicheskaya Str., 220072, Minsk

tigranbmk@gmail.comШавалдаЕ. С.ShavaldaE. S.

студент

пр. Независимости, 4, 220030, г. Минск

Student

4, Nezavisimosti Ave., 220030, Minsk

shavalda@bk.ruБатянА. Н.BatyanA. N.

д-р мед. наук, про- фессор, заведующий кафедрой

пр. Независимости, 4, 220030, г. Минск

D. Sc. (Med.), Professor, Head of the Department

4, Nezavisimosti Ave., 220030, Minsk

ant_b@tut.byИнститут физиологии НАН БеларусиInstitute of Physiology of the National Academy of Sciences of BelarusМеждународный государственный экологический институт им. А. Д. Сахарова Белорусского государственного университетаInternational Sakharov Environmental Institute of Belarusian State University2018030320181516875Copyright © Мелик-Касумов Т.Б., Шавалда Е.С., Батян А.Н., 20182018Мелик-Касумов Т.Б., Шавалда Е.С., Батян А.Н.Melik-Kasumov T.B., Shavalda E.S., Batyan A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/415

Целью настоящего исследования являлась оценка противосудорожного потенциала эндогенного липидного сигнального соединения – этаноламида стеариновой кислоты, или стеароилэтаноламина (SEA), – вещества, обладающего каннабимиметическим эффектом. В модели эпилептического припадка, вызванного инъекцией пентилентетразола (60 мг/кг), оценивали эффекты SEA в дозах 1 и 10 мг/кг. SEA вводили в смеси растворителей (спирт, полисорбат-80, физиологический раствор; 5:5:90 об. % соответственно), которая сама по себе не вызывала изменений во времени наступления или выраженности эпилептического припадка. Развитие припадков оценивали по шкале Расина. Установлено, что заблаговременная (за 30 мин) внутрибрюшинная инъекция SEA в дозе 1 мг/кг не вызывает достоверных изменений в формировании тонико-клонических припадков, вызванных пентилентетразолом. В то же время в дозе 10 мг/кг SEA увеличивает латентный период до наступления первого приступа на 58 %, а также снижает общую выраженность судорожной активности по шкале Расина на 27 %. Таким образом, SEA в дозе 10 мг/кг обладает противосудорожным действием, однако не подавляет судороги полностью. Механизмы обнаруженного действия стеароилэтаноламина нуждаются в дальнейшем уточнении. 

The purpose of this study was to determine whether stearoylethanolamine (SEA), a signaling lipid substance with cannabimimetic effects, would be effective against pentylenetetrazole induced seizure. In the pentylenetetrazole (60 mg/kg) model of acute seizure, the effects of SEA in doses of 1 and 10 mg/kg were evaluated. The vehicle for SEA consisted of alcohol, tween 80 and saline (5:5:90, vol. % accordingly) and was proved to have no effect on the seizure onset and severity by itself. Severity of seizure was estimated by Racine’s scale. It was shown that preliminary i.p. injection of SEA in a dose of 1 mg/kg made no effect on the latency before first convulsion and overall seizures severity. Nonetheless, SEA in a dose of 10 mg/kg increased the latent period before the seizure onset by 58 % and decreased the seizure severity according to Racine’s scale by 27  %. Thus, SEA produces the antiepileptic effect, but does not completely suppress seizures. The mechanism of action of SEA remains to be defined. 

эпилептический припадокпентилентетразоламиды жирных кислотстеароилэтаноламинСЭАSEAseizurepentylenetetrazolefatty acids amidesstearoylethanolamineSEAРабота выполнена при финансовой поддержке Белорусского республиканского фонда фундаментальных исследований (грант № М17-070 от 18.04.2017 г.).This work was supported by the Belarusian Republican Foundation for Fundamental Research (Grant no. M17-070 of April 18, 2017).ReferencesИсследование заболеваемости и распространенности эпилепсии в Минске / В. Докукина [и др.] // Эпилепсия и пароксизм. состояния. – 2014. – Т. 6, № 2. – С. 29–33.Dokukina T. B., Golubeva T. S., Matveichuk I. V., Mahrov M. V., Loseva V. M., Krupenkina E. V., Marchuk S. A. Study of the incidence and prevalence of epilepsy in Minsk. Epilepsiya i paroksizmal’nye sostoyaniya [Epilepsia and paroxyzmal conditions], 2014, vol. 6, no. 2, pp. 29–33 (in Russian).Löscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs / W. Löscher // Seizure. – 2011. – Vol. 20, N 5. – P. 359–368.Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, vol. 20, no. 5, pp. 359–368. DOI: 10.1016/j.seizure.2011.01.003Löscher, W. Current status and future directions in the pharmacotherapy of epilepsy / W. Löscher // Trends in Pharmacological Sciences. – 2002. – Vol. 23, N 3. – P. 113–118.Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends in Pharmacological Sciences, 2002, vol. 23, no. 3, pp. 113–118. DOI: 10.1016/s0165-6147(00)01974-xLöscher, W. New horizons in the development of antiepileptic drugs / W. Löscher, D. Schmidt // Epilepsy Res. – 2002. – Vol. 50, N 1–2. – P. 3–16.Löscher W., Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Research, 2002, vol. 50, no. 1–2, pp. 3–16. DOI: 10.1016/s0920-1211(02)00063-3Acharya, M. M. Progress in neuroprotective strategies for preventing epilepsy / M. M. Acharya, B. Hattiangady, A. K. Shetty // Progress in Neurobiology. – 2008. – Vol. 84, N 4. – Р. 363–404.Acharya M. M., Hattiangady B., Shetty A. K. Progress in neuroprotective strategies for preventing epilepsy. Progress in Neurobiology, 2008, vol. 84, no. 4, pp. 363–404. DOI: 10.1016/j.pneurobio.2007.10.010Chiurchiù, V. Bioactive lipids as modulators of immunity, inflammation and emotions / V. Chiurchiù, M. Maccarrone // Current Opinion in Pharmacology. – 2016. – Vol. 29. – P. 54–62.Chiurchiù V., Maccarrone M. Bioactive lipids as modulators of immunity, inflammation and emotions. Current Opinion in Pharmacology, 2016, vol. 29, pp. 54–62. DOI: 10.1016/j.coph.2016.06.005Hannun, Y. A. Principles of bioactive lipid signalling: lessons from sphingolipids / Y. A. Hannun, L. M. Obeid // Nature Rev. Molecular Cell Biology. – 2008. – Vol. 9, N 2. – P. 139–150.Hannun Y. A., Obeid L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Reviews Molecular Cell Biology, 2008, vol. 9, no. 2, pp. 139–150. DOI: 10.1038/nrm2329Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides / B. F. Cravatt [et al.] // Nature. – 1996. – Vol. 384, N 6604. – P. 83–87.Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 1996, vol. 384, no. 6604, pp. 83–87. DOI: 10.1038/384083a0Чурюканов, М. В. Функциональная организация и терапевтический потенциал эндогенной каннабиноидной системы / М. В. Чурюканов, В. В. Чурюканов // Эксперим. и клин. фармакология. – 2004. – Т. 67, № 2. – С. 70–78.Churyukanov M. V., Churyukanov V. V. Functional organization and therapeutic potential of the endogenous cannabinoid system. Eksperimental’naya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology], 2004, vol. 67, no. 2, pp. 70–78 (in Russian).Шубина, Л. В. Эндогенная каннабиноидная система мозга: роль в регуляции судорожной активности / Л. В. Шубина, В. Ф. Кичигина // Успехи физиол. наук. – 2012. – Т. 43, № 3. – С. 21–37.Shubina L. V., Kichigina V. F. Endogenous cannabinoid system of the brain: a role in the regulation of convulsive activity. Uspekhi fiziologicheskikh nauk [Progress in Physiology], 2012, vol. 43, no. 3, pp. 21–37 (in Russian).Hofmann, M. E. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention / M. E. Hofmann, C. J. Frazier // Experimental Neurology. – 2013. – Vol. 244. – P. 43–50.Hofmann M. E., Frazier C. J. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Experimental Neurology, 2013, vol. 244, pp. 43–50. DOI: 10.1016/j.expneurol.2011.11.047Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy / A. Romigi [et al.] // Epilepsia. – 2010. – Vol. 51, N 5. – P. 768–772.Romigi A., Bari M., Placidi F., Marciani M. G., Malaponti M., Torelli F., Izzi F., Prosperetti C., Zannino S., Corte F., Chiaramonte C., Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporallobe epilepsy.Epilepsia, 2010, vol. 51, no. 5, pp. 768–772.DOI: 10.1111/j.1528-1167.2009.02334.xPiomelli, D. The molecular logic of endocannabinoid signaling / D. Piomelli // Nature Rev. Neuroscience. – 2003. – Vol. 4, N 11. – P. 873–884.Piomelli D. The molecular logic of endocannabinoid signaling. Nature Reviews Neuroscience, 2003, vol. 4, no. 11, pp. 873–884. DOI: 10.1038/nrn1247CB1 Cannabinoid receptors and on-demand defense against excitotoxicity / G. Marsicano [et al.] // Science. – 2003. – Vol. 302, N 5642. – P. 84–88.Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S. C., Cascio M. G., Gutiérrez S. O., van der Stelt M., López-Rodriguez M. L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., Lutz B. CB1 Cannabinoid receptors and on-demand defense against excitotoxicity. Science, 2003, vol. 302, no. 5642, pp. 84–88. DOI: 10.1126/science.1088208The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities / T. Bíró [et al.] // Trends in Pharmacological Sciences. – 2009. – Vol. 30, N 8. – P. 411–420.Bíró T., Tóth B. I., Haskó G., Paus R., Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences, 2009, vol. 30, no. 8, pp. 411–420. DOI: 10.1016/j.tips.2009.05.004Bradshaw, H. B. Orphan endogenous lipids and orphan GPCRs: a good match / H. B. Bradshaw, S. H. Lee, D. McHugh // Prostaglandins and Other Lipid Mediators. – 2009. – Vol. 89, N 3–4. – P. 131–134.Bradshaw H. B., Lee S. H., McHugh D. Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins and Other Lipid Mediators, 2009, vol. 89, no. 3–4, pp. 131–134. DOI: 10.1016/j.prostaglandins.2009.04.006Влияние олеамида на судороги, вызванные у крыс пентилентетразолом / Р. Соломониа [и др.] // Бюл. экспе- рим. биологии и медицины. – 2008. – Т. 145, № 2. – С. 175–187.Solomonia R., Nozadze M., Mikautadze E., Kuchiashvili N., Kiguradze T., Abkazava D., Pkhakadze V., Mamulaishvili I., Mikeladze E., Avaliani N. Effect of oleamide on convulsions caused in rats by pentylenetetrazole. Bulletin of Experimental Biology and Medicine [Bulletin of Experimental Biology and Medicine], 2008, vol. 145, no. 2, pp. 175–187 (in Russian).Selective antiepileptic effects of N-рalmitoylethanolamide, a putative endocannabinoid / A. H. Sheerin [et al.] // Epilepsia. – 2004. – Vol. 45, N 10. – P. 1184–1188.Sheerin A. H., Zhang X., Saucier D. M., Corcoran M. E. Selective antiepileptic effects of N-рalmitoylethanolamide, a putative endocannabinoid. Epilepsia, 2004, vol. 45, no. 10, pp. 1184–1188. DOI: 10.1111/j.0013-9580.2004.16604.xВлияние N-пальмитоилэтаноламина и N-стеароилэтаноламина в липосомальной форме на заживление экспериментальных ран кожи / Т. О. Павлють [и др.] // Новости хирургии. – 2016. – № 5. – С. 425–435.Pavlyut’ T. O., Melik-Kasumov T. B., Zhavoronok I. P., Antipova O. A., Pekhtereva E. I., Novakovskaya S. A., Vasilkevich A. I., Kisel’ M. A., Molchanov A. Yu. The Effect of N-palmitoylethanolamine and N-stearoylethanolamine in liposomes on the healing of experimental skin wounds. Novosti Khirurgii [Surgery news], 2016, vol. 24, no. 5, pp. 425–435 (in Russian).Молчанова, А. Ю. Эндоканнабиноидная система: физиология, патофизиология, терапевтический потенциал / А. Ю. Молчанова. – Минск : Белорус. наука, 2015. – 212 с.Molchanova A. Yu. Endocannabinoid system: physiology, pathophysiology, therapeutic potential. Minsk, Belorusskaya nauka Publ., 2015. 212 p. (in Russian).Кардиопротекторный эффект N-стеароилэтаноламина при анафилактическом шоке у морских свинок / Н. М. Гулая [и др.] // Биомед. химия. – 2009. – Т. 55, № 6. – С. 743–749.Gulaya N. M., Berdyshev A. G., Chumak A. A., Kindruk N. L., Gorid’ko T. N. Cardioprotective effect of N-stearoylethanolamine in anaphylactic shock in guinea pigs. Biomeditsinskaya Khimiya [Biomedical Chemistry], 2009, vol. 55, no. 6, pp. 743–749 (in Russian).Hui, M. A. The dopamine system and alcohol dependence / M. A. Hui, Z. H. U. Gang // Shanghai Archives of Psychiatry. – 2014. – Vol. 26, N 2. – P. 61–68.Hui M. A., Gang Z. H. U. The dopamine system and alcohol dependence. Shanghai Archives of Psychiatry, 2014, vol. 26, no. 2, pp. 61–68. DOI: 10.3969/j.issn.1002-0829.2014.02.002Davies, M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system / M. Davies // J. of Psychiatry and Neuroscience. – 2003. – Vol. 28, N 4. – P. 263–274.Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry and Neuroscience, 2003, vol. 28, no. 4, pp. 263–274.Nitric oxide, epileptic seizures, and action of antiepileptic drugs / M. Banach [et al.] // CNS and Neurological Disorders – Drug Targets. – 2011. – Vol. 10, N 7. – P. 808–819.Banach M., Piskorska B., Czuczwar S. J., Borowicz K. K. Nitric oxide, epileptic seizures, and action of antiepileptic drugs. CNS and Neurological Disorders – Drug Targets, 2011, vol. 10, no. 7, pp. 808–819. DOI: 10.2174/187152711798072347Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system / M. Maccarrone [et al.] // Molecular and Cellular Neuroscience. – 2002. – Vol. 21, N 1. – P. 126–140.Maccarrone M., Cartoni A., Parolaro D., Margonelli A., Massi P., Bari M., Battista N., Finazzi-Agrò A. Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Molecular and Cellular Neuroscience, 2002, vol. 21, no. 1, pp. 126–140. DOI: 10.1006/mcne.2002.1164PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings / M. Puligheddu [et al.] // PLoS One. – 2013. – Vol. 8, N 5. – P. e64541.Puligheddu M., Pillolla G., Melis M., Lecca S., Marrosu F., De Montis M. G., Scheggi S., Carta G., Murru E., Aroni S., Muntoni A. L., Pistis M. PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. PLoS One, 2013, vol. 8, no. 5, p. e64541. DOI: 10.1371/journal.pone.0064541Cullingford, T. Peroxisome proliferator-activated receptor alpha and the ketogenic diet / T. Cullingford // Epilepsia. – 2008. – Vol. 49, iss. 8. – P. 70–72.Cullingford T. Peroxisome proliferator-activated receptor alpha and the ketogenic diet. Epilepsia, 2008, vol. 49, iss. 8, pp. 70–72. DOI: 10.1111/j.1528-1167.2008.01840.x

The authors declare that there are no conflicts of interest present.